SCHEMBL2010917

SCHEMBL2010917

[NH]c1ccc2ccccn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.40
ALDH1A1 P00352 8/20 0.36
KDM4E B2RXH2 7/20 0.36
MAPT P10636 3/20 0.36
CHEK1 O14757 1/20 0.36
LIMK1 P53667 1/20 0.36
MAPK14 Q16539 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSD17B10 Q99714 4/20 0.34
NPC1 O15118 3/20 0.34
HPGD P15428 3/20 0.34
GLA P06280 2/20 0.34
GAA P10253 2/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
RAB9A P51151 3/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
MAPK1 P28482 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16924635 0.70 ALOX15 (0.40) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL2010921 0.70 ALOX15 (0.40) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL4566859 0.70 KDM4E (0.41) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL277390 0.70 ALOX15 (0.40) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL277389 0.70 ALOX15 (0.40) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL13112245 0.70 ALOX15 (0.40) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL7169853 0.70 ALDH1A1 (0.37) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL9279843 0.67 ALOX15 (0.37) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL7072548 0.67 ALDH1A1 (0.47) ALOX15ALDH1A1KDM4EMAPTCHEK1
SCHEMBL29147924 0.67 ALOX15 (0.37) ALOX15ALDH1A1KDM4EMAPTCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-04-01 US disclosed
US-20100069374-A1 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-03-18 US disclosed
US-7652008-B2 2,2,7,9-tetramethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-3-ol; 3-hydroxy-2,2,9-trimethyl-4-[(2-phenylethyl)amino]-3,4-dihydro-2H-pyrano[2,3-g]quinolin-7-carbonitrile; have the prolongation effect on refractory period NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-26 US disclosed
EP-2133343-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND Nissan Chemical Industries, Ltd. (JP) 2009-12-16 EP disclosed
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-03 US disclosed
EP-1732929-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS Nissan Chemical Industries, Ltd. (JP) 2006-12-20 EP disclosed
WO-2005090357-A1 TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069374-A1 Tricyclic benzopyrane compound CBR1, CBR3, CYP2C9 ALOX15 2356/4885ALDH1A1 2252/4885KDM4E 3259/4885
US-20100081808-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE EPOXY COMPOUND OSTC, EEF1D, SQLE ALOX15 73/4885ALDH1A1 592/4885KDM4E 2563/4885
US-20080004262-A1 Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents CBR1, CBR3, SCN8A ALOX15 2135/4885ALDH1A1 2087/4885KDM4E 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.